Lipocine Doses First Participant in BLOOM PPD Trial
Lipocine announced the dosing of the first participant in its BLOOM Phase 3 trial for postpartum depression; the 48-hour oral treatment aims for at-home use, with topline results expected in 2H 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed